JACC Case Rep . Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review

[tetano]

JACC Case Rep


. 2020 Oct 28.
doi: 10.1016/j.jaccas.2020.08.025. Online ahead of print.
Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review


James C Gubitosa ¹ , Parul Kakar ² , Christine Gerula ² , Hernando Nossa ³ , Diana Finkel ³ , Kristin Wong ⁴ , Megna Khatri ⁴ , Hasan Ali ¹



Affiliations

• PMID: 33163977
• PMCID: PMC7598346
• DOI: 10.1016/j.jaccas.2020.08.025

Abstract

Remdesivir has seen extensive use during the coronavirus disease-2019 pandemic given its clinically proven efficacy against severe acute respiratory syndrome coronavirus type 2. There has been little cited regarding adverse effects. Here we present the case of a patient with marked sinus bradycardia that began acutely on initiation of remdesivir and resolved almost immediately on cessation of the drug. (Level of Difficulty: Beginner.).

Keywords: AV, atrioventricular; COVID-19, coronavirus disease-2019; ECG, electrocardiogram; LBBB, left bundle branch block; bradycardia; cancer; cardiovascular disease; chest pain; electrocardiogram; electrophysiology; h-mtRNAP, human mitochondrial RNA polymerase; lethargy; physical examination; shortness of breath.